Pharmaceutical News

RSS

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Renovis and Pfizer extend research collaboration

Renovis has announced an agreement with Pfizer to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1.

11 Apr 2007

Novalar Pharmaceuticals submits NDA for dental anesthetic reversal agent

Novalar Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for marketing approval of NV-101, a local dental anesthetic reversal agent.

11 Apr 2007

Most promising drugs in development for metabolic syndrome

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.

11 Apr 2007

Canada plans to acquire MVA-based smallpox vaccine

The Department of National Defence (DND) in Canada has issued a request for proposal for the acquisition of MVA based smallpox vaccines for the protection of 10,000 people and an option for protecting another 10,000 people.

11 Apr 2007

Boehringer Ingelheim expands license agreement with GeneGo

GeneGo has announced that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments.

11 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.

10 Apr 2007

FASgen awarded grant for refinement of its serum fatty acid synthase

FASgen has announced that it has been awarded an SBIR grant from National Cancer Institute for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS- Detect ELISA.

10 Apr 2007

Epilepsy drug retigabine safe and effective

A drug for epilepsy with a new mechanism of action is safe and effective, according to a study published in the April 10, 2007, issue of Neurology", the scientific journal of the American Academy of Neurology.

10 Apr 2007

China Medicine's ADTZ product highlighted at American Chemical Society's National Meeting

China Medicine Corporation has announced that the Company's proprietary ADTZ product was discussed as a viable means to reduce aflatoxins in the creation of ethanol based products from corn feed at the recent American Chemical Society, 233rd National Meeting Agricultural Biomass, Biobased Products, & Biofuels Symposium, which was held in Chicago, Illinois on March 25th through the 29th.

10 Apr 2007

Roche to acquire BioVeris

BioVeris Corporation has announced that the Company has reached a definitive agreement under which Roche will acquire BioVeris for $21.50 per share in cash, or a total of approximately $600 million.

From Roche Sequencing and Life Science 5 Apr 2007

Pharmacyclics undergoes 'file over protest' for Xcytrin NDA

Pharmacyclics, Inc. has announced its request to the U.S. Food and Drug Administration (FDA) that its New Drug Application (NDA) for Xcytrin (motexafin gadolinium) Injection be filed over protest.

5 Apr 2007

PhRMA statement on the Medicare prescription drug program

Pharmaceutical Research and Manufacturers of America Senior Vice President Ken Johnson issued the following statement on the AARP's campaign to modify the Medicare prescription drug program.

5 Apr 2007

Market study into the distribution of medicines in the UK

The OFT has launched a market study into the distribution of medicines in the UK. This decision follows recent and proposed distribution changes by leading UK medicine suppliers.

5 Apr 2007

Bayer Healthcare Pharmaceuticals launches in the U.S.

Bayer HealthCare Pharmaceuticals Inc. today announced its official U.S. launch. The new company incorporates the former Berlex Inc.into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

5 Apr 2007

AARP asks U.S. Senator Coleman to stand up to big pharma

AARP State President Skip Humphrey stood with a group of red-shirted AARP members and representatives of the Minnesota Senior Federation and the Elder Care Rights Alliance to urge U.S. Senator Norm Coleman to support legislation to give Medicare the authority to negotiate with drug companies for lower prescription drug prices.

5 Apr 2007

FDA approves Twinrix

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.

4 Apr 2007

Effects of changing Paracetamol pack size regulations in UK

Fatal poisonings involving paracetamol (acetaminophen) fell after a law introduced in the UK restricted the number of tablets that could be sold across the counter.

4 Apr 2007

Eli Lilly acquires Hypnion

Eli Lilly and Company has announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

3 Apr 2007